daratumumab

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma

Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon[...]

By afschroeder • July 14, 2026

Insights from daratumumab use in highly sensitized pediatric heart transplant candidates and recipients: A single-center institutional experience and outcomes

Husain M, Butler C, Fan AM, Halnon NJ, Reardon LC, Alejos JC. Insights from daratumumab use in highly sensitized pediatric heart transplant candidates and recipients:[...]

By afschroeder • August 19, 2025